View Past PerformanceSoligenix 대차대조표 건전성재무 건전성 기준 점검 6/6Soligenix 의 총 주주 지분은 $5.3M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $9.2M 및 $3.9M 입니다.핵심 정보0%부채/자본 비율US$0부채이자보상배율n/a현금US$7.94m자본US$5.29m총부채US$3.94m총자산US$9.24m최근 재무 건전성 업데이트Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash WiselyAug 20Soligenix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for its Common StockAug 16Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day PeriodDec 24Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on NasdaqMay 29Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?Sep 06Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?Apr 22모든 업데이트 보기Recent updatesSoligenix Inc Announces Interim Results from Phase 3 Flash2 Trial Evaluating Hybryte in Treatment of Cutaneous T-Cell LymphomaApr 30New major risk - Share price stability Apr 28New major risk - Revenue and earnings growth Apr 02Soligenix Inc. Announces Positive Clinical Results For HyBryte In Comparative Study Against Valchlor In Treatment Of Cutaneous T-Cell LymphomaApr 02Soligenix, Inc. Presents Hybryte Treatment Results At US Cutaneous Lymphoma Consortium Annual WorkshopMar 23Soligenix, Inc. Receives Promising Innovative Medicine Designation for SGX945 in the United KingdomMar 10Soligenix, Inc. Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for Sgx945 for the Treatment of Behcet's DiseaseFeb 26New major risk - Revenue and earnings growth Feb 13Soligenix, Inc. has filed a Follow-on Equity Offering in the amount of $3.45 million.Jan 24Soligenix, Inc. Announces Positive Clinical Results from Phase 2 Trial of Sgx945 for the Treatment of Behcet's Disease Published in Rheumatology (Oxford)Dec 18+ 1 more updateSoligenix Inc. Announces Audio Press Release on Final Confirmatory Clinical Study Being Done for Treatment of Rare DiseaseDec 13Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of Hybryte™? for the Treatment of Cutaneous T-Cell LymphomaNov 19+ 1 more updateNew major risk - Financial position Nov 09Soligenix Achieves Important Safety Milestone in Its Confirmatory Phase 3 Clinical Trial of Hybryte for the Treatment of Cutaneous T-Cell LymphomaOct 07Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell LymphomaOct 01Soligenix, Inc. has completed a Follow-on Equity Offering in the amount of $7.500006 million.Sep 30New major risk - Market cap size Sep 23Soligenix, Inc. has filed a Follow-on Equity Offering in the amount of $7.999998 million.Sep 20Soligenix, Inc. Announces Publication Recommending Long-Term High Temperature Stability of Protein Subunit Vaccines forbola and Related VirusesSep 04Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash WiselyAug 20Soligenix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for its Common StockAug 16Soligenix Inc. Announces Audio Press Release on Promising First-Line Therapy for Rare Skin CancerAug 08New major risk - Share price stability Jul 31Soligenix, Inc. Completes its Phase 2a Proof of Concept Study Evaluating SGX945 (Dusquetide) in Treatment of Behcet's Disease and Achieves Study Objective of Demonstrating Biological EfficacyJul 31Soligenix, Inc. Announces Synthetic Hypericin Successfully Manufactured At Sterling Pharma SolutionsJul 02Soligenix, Inc. Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte in Ongoing Clinical TrialsJun 06First quarter 2025 earnings released: US$1.06 loss per share (vs US$2.91 loss in 1Q 2024) May 12Soligenix, Inc., Annual General Meeting, Jun 20, 2025May 06Soligenix, Inc. Announces Interim Results from the Ongoing Open-Label, Investigator-Initiated Study Evaluating Extended HyBryteApr 14Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) Mar 26No longer forecast to breakeven Mar 26Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryteJan 15Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell LymphomaDec 16Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell LymphomaNov 20Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's DiseaseNov 14Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) Nov 10Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer ConferenceOct 07Consensus revenue estimates decrease by 28%, EPS upgraded Aug 16Price target decreased by 13% to US$35.00 Aug 12Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 11Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™Aug 02Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell LymphomaJul 10Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell LymphomaJun 25Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell LymphomaMay 18Consensus revenue estimates decrease by 13%, EPS upgraded May 17Price target decreased by 29% to US$2.50 May 15First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 13Soligenix, Inc., Annual General Meeting, May 23, 2024May 01Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South AfricaApr 27Consensus EPS estimates upgraded to US$0.63 loss Apr 25Price target increased by 7.7% to US$3.50 Apr 12Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines AgencyApr 04Consensus revenue estimates decrease by 11%, EPS upgraded Mar 22Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 17No longer forecast to breakeven Mar 17Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory BoardFeb 08FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's DiseaseJan 09Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate PsoriasisJan 05Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg VirusesJan 02Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day PeriodDec 24New major risk - Share price stability Dec 01Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's DiseaseNov 30Consensus EPS estimates upgraded to US$0.83 loss, revenue downgraded Nov 20Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 16Price target decreased by 35% to US$3.25 Nov 14Insufficient new directors Nov 14Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens EnrollmentAug 11Soligenix, Inc., Annual General Meeting, Sep 21, 2023Aug 08Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate PsoriasisJul 12Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, IncJul 10Consensus revenue estimates increase by 13% May 31Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on NasdaqMay 29First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 18Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell LymphomaMay 12Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell LymphomaMay 05Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of DirectorsMay 04No longer forecast to breakeven Apr 08Consensus revenue estimates decrease by 76%, EPS upgraded Apr 06No longer forecast to breakeven Apr 04Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell LymphomaFeb 15Insufficient new directors Nov 17Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 13Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma Oct 05U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer Sep 12Soligenix announces $2.6M FDA grant to further study blood cancer candidate Sep 06Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?Sep 06Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 13Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M Aug 12Soligenix, SERB Pharma team up to develop therapy for ricin poisoning Jul 25Price target decreased to US$3.88 May 20First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 14Insufficient new directors Apr 27Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?Apr 22재무 상태 분석단기부채: SNGX 의 단기 자산 ( $8.8M )이 단기 부채( $3.7M ).장기 부채: SNGX의 단기 자산($8.8M)이 장기 부채($244.1K)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: SNGX 부채가 없습니다.부채 감소: SNGX는 5년 전 부채 대비 자본 비율이 274.7%였으나 현재 부채가 없습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: SNGX 은 마지막 보고 무료 현금 흐름을 기준으로 9 개월 동안 충분한 현금 활주로를 보유하고 있지만 이후 추가 자본을 조달했다.예측 현금 활주로: SNGX 은 잉여현금흐름추정을 기준으로 9 개월 동안 충분한 현금 활주로를 확보할 것으로 예상되지만 이후 추가 자본을 조달했습니다.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/03 02:05종가2026/05/01 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Soligenix, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관James MolloyAlliance Global PartnersAndrew D'SilvaB. Riley Securities, Inc.Keith MarkeyGriffin Securities1명의 분석가 더 보기
Soligenix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for its Common StockAug 16
Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day PeriodDec 24
Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on NasdaqMay 29
Soligenix Inc Announces Interim Results from Phase 3 Flash2 Trial Evaluating Hybryte in Treatment of Cutaneous T-Cell LymphomaApr 30
Soligenix Inc. Announces Positive Clinical Results For HyBryte In Comparative Study Against Valchlor In Treatment Of Cutaneous T-Cell LymphomaApr 02
Soligenix, Inc. Presents Hybryte Treatment Results At US Cutaneous Lymphoma Consortium Annual WorkshopMar 23
Soligenix, Inc. Receives Promising Innovative Medicine Designation for SGX945 in the United KingdomMar 10
Soligenix, Inc. Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for Sgx945 for the Treatment of Behcet's DiseaseFeb 26
Soligenix, Inc. Announces Positive Clinical Results from Phase 2 Trial of Sgx945 for the Treatment of Behcet's Disease Published in Rheumatology (Oxford)Dec 18+ 1 more update
Soligenix Inc. Announces Audio Press Release on Final Confirmatory Clinical Study Being Done for Treatment of Rare DiseaseDec 13
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of Hybryte™? for the Treatment of Cutaneous T-Cell LymphomaNov 19+ 1 more update
Soligenix Achieves Important Safety Milestone in Its Confirmatory Phase 3 Clinical Trial of Hybryte for the Treatment of Cutaneous T-Cell LymphomaOct 07
Soligenix, Inc. Announces Publication Recommending Long-Term High Temperature Stability of Protein Subunit Vaccines forbola and Related VirusesSep 04
Soligenix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for its Common StockAug 16
Soligenix Inc. Announces Audio Press Release on Promising First-Line Therapy for Rare Skin CancerAug 08
Soligenix, Inc. Completes its Phase 2a Proof of Concept Study Evaluating SGX945 (Dusquetide) in Treatment of Behcet's Disease and Achieves Study Objective of Demonstrating Biological EfficacyJul 31
Soligenix, Inc. Announces Synthetic Hypericin Successfully Manufactured At Sterling Pharma SolutionsJul 02
Soligenix, Inc. Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte in Ongoing Clinical TrialsJun 06
Soligenix, Inc. Announces Interim Results from the Ongoing Open-Label, Investigator-Initiated Study Evaluating Extended HyBryteApr 14
Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryteJan 15
Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell LymphomaDec 16
Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell LymphomaNov 20
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's DiseaseNov 14
Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer ConferenceOct 07
Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™Aug 02
Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell LymphomaJul 10
Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell LymphomaJun 25
Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell LymphomaMay 18
Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South AfricaApr 27
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines AgencyApr 04
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's DiseaseJan 09
Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate PsoriasisJan 05
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg VirusesJan 02
Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day PeriodDec 24
Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's DiseaseNov 30
Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens EnrollmentAug 11
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate PsoriasisJul 12
Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on NasdaqMay 29
Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell LymphomaMay 12
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell LymphomaMay 05
Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell LymphomaFeb 15
